RNA Interference Therapeutics Market - By Product Type, By Application, By Route of Administration, By End Use - Global Forecast, 2025-2034

RNA Interference Therapeutics Market Size

The global RNA interference therapeutics market was valued at USD 2.7 billion in 2024. The market is expected to grow from USD 3.1 billion in 2025 to USD 11.2 billion in 2034, at a CAGR of 15.4% during the forecast period, according to the latest report published by Global Market Insights Inc. The RNAi therapeutics market is rapidly expanding due to the growth of genetic research, the increasing incidence of rare genetic diseases, and the growing burden of chronic diseases.

By interfering with the genetic sequences of a disease, RNAi therapeutics address an unmet need in the treatment of diseases such as amyloidosis, acute hepatic porphyria, and hypercholesterolemia.
 

The introduction of clinically safe and effective RNAi delivery technologies such as lipid nanoparticles (LNPs) and conjugate-based approaches has expanded the clinical uses of RNAi. The rapid advancement of technology and delivery methods have constructed a paved pathway for strong collaborations in the industry, particularly for the drug development process. Strategic partnerships, such as those between Alnylam Pharmaceuticals and Regeneron, and between Dicerna and Novo Nordisk, underscore the growing commercial interest in RNAi.
 

RNAi therapeutics are administered using small interfering RNAs (siRNAs) or microRNAs (miRNAs) that degrade or suppress messenger RNA (mRNA) to inhibit protein synthesis. The market is dominated by companies such as Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Silence Therapeutics, and Novo Nordisk, who are broadening their reach through regulatory approvals and commercialization.
 

The global RNAi therapeutics market has grown from USD 1.8 billion in 2021 to USD 2.4 billion in 2023 and is expected to expand further as regulatory agencies increase support for RNA-based treatments. There are also advancements in the combination of RNAi with other cutting-edge therapies such as CRISPR and antisense oligonucleotides, which is aimed at boosting the desired therapeutic impact. Artificial intelligence (AI) for drug discovery is helping the industry identify and prioritize RNAi therapies that are closer to commercialization. For example, machine learning algorithms now assist in optimizing siRNA sequences for higher efficacy and lower off-target effects.
 

Market drivers include the rise of personalized medicine, the increasing prevalence of chronic liver and metabolic conditions, and the international movement toward innovative gene therapies. Moreover, the sustained interest in orphan drugs and rare diseases provides RNAi developers with regulatory advantages, including accelerated approvals and extended market exclusivity. With diversification and stronger scientific backing, the RNAi therapeutic market is likely to become pivotal in the evolution of medicine.
 

RNA Interference Therapeutics Market Trends

• The RNAi therapeutics market is undergoing a pivotal shift as it moves from early-stage research into broader clinical application. Progress in delivery systems, regulatory advances, and increased investments in RNA technologies from the government and academia are driving market growth.
   
• As of 2025, the U.S. Food and Drug Administration (FDA) has approved a total of 21 RNA-based therapeutics, 6 of which are RNAi therapeutics. These approvals underscore the therapeutic value of RNAi, particularly in addressing conditions that were previously difficult or impossible to treat. In support of this, 48 clinical trials that utilize RNAi therapeutics are currently underway. This demonstrates an active interest in research and clinical development pertaining to RNAi therapeutics.
   
• Small interfering RNAs (siRNAs) dominate RNAi technologies due to their specificity and compatibility with novel advanced delivery technologies. Delivery strategies such as GalNAc conjugates for liver-targeted subcutaneous administration and lipid nanoparticles (LNPs) for systemic delivery are standardizing across trials, improving tissue targeting and reducing systemic side effects. RNAi technology has shifted to target more challenging conditions, such as cardiovascular, oncological, neurological, and metabolic disorders, rather than the previously exclusive focus on liver disorders.
   
• The expansion of this field has also been the result of public sector support. Government funding of research has been a catalyst to early-stage development of RNAi and the fostering of academic-industry alliances.
   
• The development process is being further accelerated by AI-driven design technologies, enabling researchers to efficiently tailor siRNA sequences, minimize off-target effects, and optimize delivery systems. In anticipation of the clinical and later commercial needs, CDMOs are also expanding their oligonucleotide manufacturing portfolio.
   
• The RNAi field is still being researched and commercialized primarily in North America, although the Asia-Pacific region is gaining on it quickly, spurred by increased investments in biotech, greater clinical activity, and improved regulatory frameworks.
   
• The convergence of clinical validation, institutional support, and technological advancements has triggered a transformation in the field of RNAi therapeutics, which is now an essential part of precision medicine.
   

RNA Interference Therapeutics Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

Based on product type, the global RNA interference therapeutics market is divided into small interfering RNA (siRNA), microRNA (miRNA), short hairpin RNA (shRNA), and other product types. The siRNA segment accounted for 59.8% of the market in 2024. The segment is expected to exceed USD 6.8 billion by 2034, growing at a CAGR of 15.5% during the forecast period.
 

• The siRNA segment represents the most advanced and clinically validated category within RNAi therapeutics. siRNAs function by selectively silencing specific genes through mRNA degradation, offering high target specificity and reduced off-target activity.
   
• As of 2025, all six FDA-approved RNAi therapeutics patisiran, givosiran, lumasiran, inclisiran, vutrisiran, and nedosiran are siRNA-based, underscoring the segment's clinical maturity. siRNAs have proven to be very useful in treating liver disorders, as they can be effectively delivered to the liver, hepatocyte cells via GalNAc conjugation.
   
• As noted by the National Institutes of Health, 48 clinical trials investigating RNAi therapeutics are currently in progress, most of which are based on the siRNA technology. Enhanced siRNA stability and bioavailability are the result of advanced chemical modifications, and delivery systems.
   
• There are enhanced delivery systems and new insights in gene expression that are the drivers for expansion of RNAi therapeutics into new areas outside of the liver, targeting the cardiovascular, metabolic, and rare genetic disorders.
   

Based on the application, the RNA interference therapeutics market is segmented into cancer, genetic disorders, cardiovascular diseases, viral infections, neurodegenerative diseases, ophthalmic disorders, respiratory disorders, and other applications. The genetic disorders segment dominated the market in 2024 with a revenue of USD 684 million.
 

• Currently, the genetic disorders application area is the most dominant for RNAi, especially for siRNA drugs. This is due to the ability of siRNA to specifically target the genes responsible for a particular disease, and the potential to treat very rare and previously untreatable inherited diseases.
   
• Several of the FDA-approved siRNA therapeutics, including patisiran for hereditary transthyretin amyloidosis, givosiran for acute hepatic porphyria, and lumasiran for primary hyperoxaluria, reflect the successful clinical translation of the potential of RNAi technology.
   
• Most of the RNAi clinical trials are focused on genetic disorders, which indicates the continuing investment in this area. The current focus of these therapies is on the liver-based genetic diseases utilizing advanced delivery systems such as GalNAc conjugates for targeted delivery to the liver cells.
   
• In addition, new innovations are developing new ways to target disorders with different tissues, demonstrating the expanding potential of RNAi. This segment continues to propel the clinical and commercial growth of the RNAi market due to robust regulatory approvals and increasing patient demand.

Learn more about the key segments shaping this market

Download Free PDF

Based on route of administration, the RNA interference therapeutics market is classified into intravenous (IV), subcutaneous (SC), and other route of administration. The subcutaneous segment dominated the market in 2024 and is growing with a CAGR of 15.4% during the forecast period.
 

• SC administration is the most common route of administration for RNAi therapeutics. It is preferred for its less invasive nature and its ease of administration and patient acceptance compared to IV delivery.
   
• A main reason for the dominance of SC delivery is the development of GalNAc conjugated siRNA technologies that enable liver-direct delivery with simple subcutaneous injections.
   
• The targeted delivery system allows for more effective therapeutics because it decreases systemic exposure and side effects. SC delivery has proven its clinical value with multiple FDA-approved RNAi drugs, including inclisiran and lumasiran.
   
• Additionally, SC administration supports outpatient treatment and reduces the need for hospital visits, benefiting both patients and healthcare systems.
   

Based on end use, RNA interference therapeutics market is classified into hospitals and clinics, research laboratories, and other end users. The hospitals and clinics segment dominated the market in 2024 and is expected to reach USD 6.1 billion by 2034.
 

• Hospitals and clinics segment is crucial in the RNAi therapeutics market. It is responsible for the direct administration of therapeutics and the monitoring of patients.
   
• Healthcare facilities have the structural components necessary for the safe and effective administration of RNAi drugs, particularly those delivered by subcutaneous or intravenous routes. Hospitals and clinics provide essential patient education, dosage adjustments, and the monitoring of adverse events that contribute to the success of these innovative treatments.
   
• As the number of approved RNAi therapeutics for the treatment of genetic and rare diseases increases, the integration of RNAi treatment into standard care practices will continue to improve.
   
• Moreover, specialized clinics that cater to rare diseases and genetic disorders are increasing their capabilities for administering RNAi therapy, which expands patient access and enhances treatment efficacy for diverse of populations.

Looking for region specific data?

Download Free PDF

North America RNA interference therapeutics market
 

The North America market dominated the market with a market share of 45.7% in 2024.
 

• North America dominates the RNAi therapeutics market, because of its excellent healthcare system, robust research infrastructure, and first implementation of new therapies.
   
• North America’s dominance is also attributed to the large investments made by the National Institutes of Health (NIH) as well as the key players and contract development and manufacturing organizations (CDMOs) in the area, who facilitate research and development of the RNAi therapeutics drugs for rare and genetic diseases.
   
• A growing focus on precision medicine, favorable regulatory pathways, and rising prevalence of genetic disorders continue to drive RNAi adoption in North America.
   

The U.S. RNA interference therapeutics market was valued at USD 762.1 million and USD 872.3 million in 2021 and 2022, respectively. The market size reached USD 1.1 billion in 2024, growing from USD 1 billion in 2023.
 

• The U.S. RNAi therapeutics market continues to lead global innovations in RNAi, facilitated by strong clinical adoption, research and development, and regulatory support. The U.S. has a distinct advantage due to the National Institutes of Health (NIH) and other government bodies which provide funding and promote research on RNA-based therapeutics.
   
• U.S. biotech companies also forefront most of the global pipeline due to the strong healthcare system and specialized clinical facilities. With the growing demand for more customized medicine and the wider use of RNAi, the U.S. continues to lead in market growth and innovation.
  
   

Europe RNA interference therapeutics market
 

Europe market accounted for USD 767.8 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• Market growth of RNAi therapeutics is encouraged by academic research, the precision medicine movement, and the advancements of regulatory approval for therapeutic interventions within Europe.
   
• The European Medicines Agency (EMA) has approved several RNAi-based therapies, including patisiran and inclisiran, for use across EU member states.
   
• Germany, the UK, and France have most of the clinical trial and adoption activities, particularly for rare and/or genetic metabolic disorders.
   
• Significant innovation is fostered by collaborative research between the academic, clinical, and biotech corporate sectors. Europe remains a key region in advancing RNAi-based treatment and clinical development.
   

Germany dominates the European RNA interference therapeutics market, showcasing strong growth potential.
 

• Germany's strong growth in the market can be attributed to the strength of its biotechnology sector, the advanced healthcare systems and infrastructure, and the active clinical research ecosystem within the nation.
   
• The country hosts numerous RNAi-related clinical trials and collaborates closely with both academic institutions and global biotech companies. Supportive regulatory policies and government funding for rare and genetic disease research further boost market growth.
   
• Germany's concentration on personalized medicine and pioneering work in RNA therapeutics has made it the most innovative nation in Europe for the adoption and development of RNAi therapies.
  
   

Asia Pacific RNA interference therapeutics market
 

The Asia Pacific market is anticipated to grow at the highest CAGR of 15.9% during the analysis timeframe.
 

• Asia Pacific’s RNAi therapeutics market is developing to become the most rapidly growing region in the world, boosted by the growing biotechnological industries, increasing healthcare investments and growing awareness of the region’s genetic disorders.
   
• China, Japan, and South Korea lead the region with their growing clinical trial activities and collaborations between domestic biotech and global pharma companies.
   
• Market growth is also unparalleled because of supportive policy initiatives that emphasize approval of innovative therapies, increasing demand for personalized medicine, and access to sophisticated therapies.
   

China RNA interference therapeutics market is estimated to grow with a significant CAGR, in the Asia Pacific market.
 

• Investment in biotechnology, emerging domestic biotech companies, and increasing demand of high-end genetic therapies have been driving the growth for the China RNAi therapeutics market.
   
• In the field of RNAi, China is heavily involved in clinical trials and partnerships with global pharma in genetic therapies. The regulatory approval of innovative therapeutics and participation in RNAi clinical trials are deepening collaborations with global pharma players.
   
• China’s large patient population combined with growing research and development capabilities position the country to be a significant participant in the global landscape of RNAi therapeutics.
  
   

Latin American RNA interference therapeutics market
 

Brazil leads the Latin American market, exhibiting remarkable growth during the analysis period.
 

• Brazil continues to dominate the market for Latin America and displayed remarkable growth during the analysis period.
   
• The RNAi therapeutics market in Brazil is early in its life cycle but is showing high market growth due to rising awareness around genetics and rare diseases, government interest in precision medicine, and the expansion of Brazil’s healthcare infrastructure.
   
• Brazilian research institutions are starting to study the potential of RNA technologies, usually in collaboration with global partners. Although local clinical trial activity is limited, the growth of the biotechnology sector and improving regulations for the healthcare may strengthen the market.
  
   

Middle East and Africa RNA interference therapeutics market
 

Saudi Arabia market to experience substantial growth in the Middle East and Africa market in 2024.
 

• The Saudi Arabia RNAi therapeutics market is gradually emerging, supported by the country’s strategic focus on advancing healthcare and biotechnology under Vision 2030.
   
• Saudi Arabia's investment in genomic research and personalized medicines, as well as the treatment of rare diseases, provide the groundwork necessary for the adoption of RNAi therapeutics. The country’s leading universities and research institutes, with the assistance of foreign collaborators, are studying the development of RNA-based therapies.
   
• While the number of clinical trials remains low, anticipated improvements in healthcare and the reformed regulatory environment are expected to foster growth. Saudi Arabia aims to position itself as a regional hub for advanced therapeutic technologies, including RNAi.
   

RNA Interference Therapeutics Market Share

The RNAi therapeutics market features a dynamic and moderately consolidated competitive landscape, shaped by a mix of established biopharmaceutical companies, RNA-focused biotech firms, and emerging RNA platform innovators. Leading players such as Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Novo Nordisk, Silence Therapeutics, and Novartis collectively account for a ~80% market share, driven by robust pipelines, strategic licensing agreements, and first-to-market RNAi drug approvals.
 

To strengthen their market position, these companies are leveraging multi-pronged strategies, including strategic alliances with big pharma, co-development deals, expansion of GalNAc and LNP delivery platforms, and geographic market penetration. Their focus remains on advancing RNAi drugs for rare genetic diseases, cardiometabolic disorders, and hepatic conditions, while integrating AI in drug design and delivery optimization.
 

Emerging players are contributing through innovations in non-hepatic delivery systems, extrahepatic targeting, and scalable manufacturing. Their growing presence is particularly evident in Asia-Pacific, Europe, and the Middle East, where increasing genomic research, government funding, and biotech infrastructure are accelerating RNAi therapeutic development and adoption.
 

RNA Interference Therapeutics Market Companies

The company profile section includes both companies that have commercial drug available in the market as well as those that are onto clinical phase development. Prominent players operating in the market are as mentioned below:
 

• Alnylam Pharmaceuticals
• Arbutus Biopharma
• Arrowhead Pharmaceuticals
• Atalanta Therapeutics
• Benitec Biopharma
• Creative Biogene
• Novartis
• Novo Nordisk
• OliX Pharmaceuticals
• Sanofi
• Silence Therapeutics
• Sirnaomics

• Alnylam Pharmaceuticals

Alnylam is a pioneer in RNAi therapeutics and holds the first FDA approvals in the field, including givosiran. Its proprietary GalNAc delivery platform enables targeted liver delivery, supporting a strong pipeline for rare genetic and hepatic diseases.
 

• Novo Nordisk

Through its acquisition of Dicerna Pharmaceuticals, Novo Nordisk has expanded into RNAi therapeutics, focusing on cardiometabolic and endocrine disorders. The company leverages Dicerna’s GalXC platform to develop RNAi candidates that complement its existing diabetes and obesity treatment portfolio.
 

• Novartis

Novartis is advancing RNAi-based therapies primarily through its partnership with Alnylam on inclisiran, a siRNA therapy for lowering LDL cholesterol. Its USP lies in integrating RNAi with large-scale commercialization and cardiovascular expertise to deliver long-acting, infrequent-dosing solutions.
 

RNA Interference Therapeutics Industry News

• In March 2025, Alnylam Pharmaceuticals launched Qfitlia (fitusiran), an innovative RNA interference (RNAi) therapeutic for treating hemophilia. The FDA granted approval for Qfitlia, which represents a significant advancement in gene silencing therapies for bleeding disorders.
   
• In July 2024, Sirnaomics entered in a partnership with Gore Range Capital LLC to advance RNAi therapies specifically for aesthetic medicine. This collaboration will explore novel RNAi applications in skin rejuvenation and other cosmetic treatments.
   
• In September 2022, Alnylam Pharmaceuticals received approval from the European Commission to market AMVUTTRA. This RNAi therapy targets hereditary transthyretin-mediated (hATTR) polyneuropathy and offers a major treatment breakthrough for adults with this rare condition.
   
• In April 2025, Arrowhead Pharmaceuticals reported the successful completion of phase 2 trials for ARO-HIF2, an RNAi-based therapy targeting renal cell carcinoma. The treatment showed promising efficacy in reducing tumor growth markers.
   

The RNA interference therapeutics market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Small interfering RNA (siRNA)
• MicroRNA (miRNA)
• Short hairpin RNA (shRNA)
• Other product types  

Market, By Application

• Cancer
• Genetic disorders
• Cardiovascular diseases
• Viral infections
• Neurodegenerative diseases
• Ophthalmic disorders
• Respiratory disorders
• Other applications

Market, By Route of Administration

• Intravenous (IV)
• Subcutaneous (SC)
• Other route of administration

Market, By End Use

• Hospitals and clinics
• Research laboratories
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE